Kansas

Researchers are evaluating the effectiveness of iberdomide maintenance therapy compared to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in adults with newly diagnosed multiple myeloma. This phase 3 study aims to determine which maintenance treatment better supports patients following their initial transplant and induction therapies. Participants must have responded to prior treatments and undergone ASCT within specified time frames. Participants will receive either iberdomide or lenalidomide at specified doses on scheduled days as maintenance therapy after their ASCT. The study is randomized, multi-center, and open-label, meaning both participants and researchers know which treatment is given. The treatments will be administered following a standard induction therapy including proteasome inhibitors, immunomodulatory drugs, and possibly monoclonal antibodies, with or without consolidation after transplant. Throughout the study, participants will be monitored for progression-free survival for up to 6 years to assess how well the maintenance therapies prevent disease progression. Researchers will also evaluate safety and treatment response according to established myeloma criteria. Regular assessments will include clinical evaluations and monitoring for any signs of disease relapse or adverse effects over the long term.

This research focuses on people with progressive pulmonary fibrosis or idiopathic pulmonary fibrosis (IPF) who have already completed a previous Avalyn Pharma study involving an inhaled antifibrotic medication, such as AP01. The trial aims to evaluate the long-term safety and tolerability of Avalyn's inhaled antifibrotic drug over an average of 6 years. It is an open-label extension study where all participants continue receiving treatment after their initial study completion. Participants will receive 100 mg of pirfenidone inhalation solution (AP01) twice daily through the eFlow Nebulizer System. The study includes a Screening/Baseline Visit, an open-label Treatment Period where the study drug is administered, and a Follow-up/End of Study phone call about two weeks after the last dose. Participants will start this extension on the same day they complete their previous study's final dose. During the study, adherence will be tracked using a paper dosing diary and by collecting any unused medication. Assessments include safety and tolerability monitoring throughout the long-term treatment period. The total participation lasts through the end of the study, with follow-up calls to evaluate ongoing safety after treatment ends.